With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?

After public scrutiny and a phone call, President Donald Trump convinced Pfizer to at least defer its drug increases. But not all companies have flinched at the president’s “We will respond” threat, including makers of some of the world’s best-selling drugs.